86 related articles for article (PubMed ID: 22110188)
1. Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo.
Kobunai T; Watanabe T; Fukusato T
Anticancer Res; 2011 Nov; 31(11):3691-6. PubMed ID: 22110188
[TBL] [Abstract][Full Text] [Related]
2. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
5. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
6. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
8. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
9. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
10. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
11. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
12. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells.
Fukuda K; Saikawa Y; Takahashi M; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Kitagawa Y
Int J Oncol; 2012 Apr; 40(4):975-82. PubMed ID: 22139134
[TBL] [Abstract][Full Text] [Related]
14. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
16. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Tanizaki J; Okamoto I; Takezawa K; Tsukioka S; Uchida J; Kiniwa M; Fukuoka M; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1198-207. PubMed ID: 20424000
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism.
Cai JP; Chen W; Hou X; Liang LJ; Hao XY; Yin XY
Anticancer Drugs; 2013 Nov; 24(10):1020-9. PubMed ID: 23941814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]